Krystal Biotech financials
$335.06−0.60%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $119.2M | $116.4M | $107.1M | $97.8M | $96.0M | $88.2M | $91.1M | $83.8M | $70.3M | $45.3M | $42.1M | $8.6M |
| Gross profit | $112.8M | $110.0M | $100.5M | $93.5M | $88.9M | $83.2M | $86.2M | $77.2M | $64.3M | $42.8M | $39.3M | $8.3M |
| Gross margin | 94.6% | 94.6% | 93.8% | 95.6% | 92.5% | 94.3% | 94.6% | 92.0% | 91.5% | 94.7% | 93.2% | 97.4% |
| Operating income | $58.4M | $53.7M | $44.3M | $41.4M | $39.4M | $36.3M | $41.4M | $22.5M | $8.6M | -$6.7M | $3.1M | -$26.0M |
| Net income | $54.8M | $55.9M | $51.4M | $79.4M | $38.3M | $35.7M | $45.5M | $27.2M | $15.6M | $932.0K | $8.7M | $80.7M |
| Net margin | 45.9% | 48.1% | 48.0% | 81.2% | 39.9% | 40.5% | 49.9% | 32.4% | 22.2% | 2.1% | 20.6% | 943.7% |
| Diluted EPS | $1.79 | $1.83 | $1.69 | $2.66 | $1.29 | $1.20 | $1.51 | $0.91 | $0.53 | $0.03 | $0.29 | $2.79 |
| EBITDA | $59.8M | $55.2M | $45.8M | $42.8M | $40.7M | $37.7M | $42.7M | $36.3M | $22.9M | -$5.3M | $3.1M | -$24.9M |
| Operating cash flow | $74.8M | $80.4M | $77.5M | $39.7M | $52.7M | $31.0M | $52.8M | $58.9M | -$4.2M | $15.9M | -$7.2M | -$21.2M |
| Free cash flow | $71.2M | $73.2M | $75.4M | $38.0M | $50.8M | $24.8M | $52.0M | $57.8M | -$5.3M | $14.6M | -$9.1M | -$23.0M |
| Diluted shares | 30.7M | 30.5M | 30.4M | 29.8M | 29.7M | 29.9M | 30.1M | 29.9M | 29.6M | 29.3M | 29.7M | 28.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $427.7M | $501.3M | $496.3M | $392.6M | $353.8M | $308.8M |
| Short-term investments | $417.9M | $322.1M | $331.5M | $338.5M | $328.2M | $308.1M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.50B | $1.40B | $1.33B | $1.24B | $1.14B | $1.07B |
| Total liabilities | $141.5M | $120.2M | $114.2M | $102.2M | $97.7M | $89.7M |
| Shareholders' equity | $1.36B | $1.28B | $1.22B | $1.14B | $1.04B | $984.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology